| metastatic/advanced RCC (mRCC) - 1st line (L1) | |||
| metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 negative | mRCC - L1 - PDL1 positive | |
| atezolizumab based treatment | |||
| atezolizumab alone | IMmotion-150 ... | IMmotion-150 ... | |
| atezolizumab plus bevacizumab | IMmotion-151 ... IMmotion-150 ... | IMmotion-151 ... | IMmotion-150 ... IMmotion-151 ... |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
